177 related articles for article (PubMed ID: 37437885)
1. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
[TBL] [Abstract][Full Text] [Related]
2. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
Bradley LD; Singh SS; Simon J; Gemzell-Danielsson K; Petersdorf K; Groettrup-Wolfers E; Ren X; Zvolanek M; Seitz C
Fertil Steril; 2019 Feb; 111(2):240-248. PubMed ID: 30527839
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.
Gemzell-Danielsson K; Heikinheimo O; Zatik J; Poka R; Rechberger T; Hudecek R; Petersdorf K; Ramirez F; Faustmann T; Groettrup-Wolfers E; Seitz C
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():7-14. PubMed ID: 32559602
[TBL] [Abstract][Full Text] [Related]
5. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
[TBL] [Abstract][Full Text] [Related]
7. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids.
Seitz C; Bumbuliene Ž; Costa AR; Heikinheimo O; Heweker A; Hudeček R; Jacquemyn Y; Melis GB; Parashar P; Rechberger T; Sánchez AC; van Aken B; Zatik J; Gemzell-Danielsson K
Contemp Clin Trials; 2017 Apr; 55():56-62. PubMed ID: 28185997
[TBL] [Abstract][Full Text] [Related]
9. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
10. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
[TBL] [Abstract][Full Text] [Related]
12. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
Diamond MP; Stewart EA; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod Open; 2019; 2019(4):hoz027. PubMed ID: 31777761
[TBL] [Abstract][Full Text] [Related]
13. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
[TBL] [Abstract][Full Text] [Related]
14. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
16. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
Donnez J; Taylor HS; Stewart EA; Bradley L; Marsh E; Archer D; Al-Hendy A; Petraglia F; Watts N; Gotteland JP; Bestel E; Terrill P; Loumaye E; Humberstone A; Garner E
Lancet; 2022 Sep; 400(10356):896-907. PubMed ID: 36116480
[TBL] [Abstract][Full Text] [Related]
17. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Elagolix for the Treatment of Heavy Menstrual Bleeding in Patients With Uterine Leiomyomas: A Randomized Controlled Trial.
Brown E; Kroll R; Li H; Ng J; Pinsky B; Rodriguez JW; Thomas J; Snabes MC
Obstet Gynecol; 2023 Nov; 142(5):1068-1076. PubMed ID: 37769311
[TBL] [Abstract][Full Text] [Related]
19. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]